FY2024 EPS Estimates for G1 Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Analysts at HC Wainwright upped their FY2024 EPS estimates for G1 Therapeutics in a research note issued on Tuesday, June 25th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.56) for the year, up from their prior forecast of ($0.61). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for G1 Therapeutics’ Q4 2024 earnings at ($0.02) EPS, FY2025 earnings at ($0.03) EPS and FY2026 earnings at ($0.11) EPS.

Several other brokerages also recently weighed in on GTHX. Needham & Company LLC reduced their target price on shares of G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday. Wedbush reiterated an “outperform” rating and set a $3.00 price objective (down from $5.00) on shares of G1 Therapeutics in a research report on Monday.

G1 Therapeutics Stock Performance

Shares of GTHX opened at $2.25 on Thursday. The firm has a fifty day moving average of $3.63 and a 200-day moving average of $3.58. The company has a market cap of $117.63 million, a price-to-earnings ratio of -3.63 and a beta of 1.71. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.55 and a current ratio of 2.94. G1 Therapeutics has a 1 year low of $1.08 and a 1 year high of $6.14.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The company had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. During the same quarter in the prior year, the firm earned ($0.53) EPS.

Institutional Trading of G1 Therapeutics

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in G1 Therapeutics by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,081,573 shares of the company’s stock worth $8,992,000 after purchasing an additional 99,900 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of G1 Therapeutics by 643.2% in the first quarter. Acadian Asset Management LLC now owns 433,709 shares of the company’s stock valued at $1,873,000 after buying an additional 375,354 shares during the period. abrdn plc bought a new position in G1 Therapeutics during the fourth quarter valued at about $1,293,000. Jacobs Levy Equity Management Inc. grew its holdings in G1 Therapeutics by 20.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,858 shares of the company’s stock worth $1,632,000 after acquiring an additional 64,790 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock worth $294,000 after acquiring an additional 82,879 shares in the last quarter. 24.21% of the stock is owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.